Anti-PD-1 Antibody Affinity Tuning for Tumor Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune therapies fail to effectively modulate the activity of immunoinhibitory proteins like PD-1, leading to immune evasion by cancer cells and inadequate immune response against tumors and chronic infections.
Innovation Solution
Development of high-affinity and specific anti-PD-1 antibody molecules for administering at fixed doses to enhance immune activation and inhibit tumor growth, combined with other therapeutic agents to optimize immune response stages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-affinity anti-PD-1 antibody molecules are developed to inhibit PD-1 signaling, then immune activation is enhanced and tumor immunosuppression is reduced, but the complexity of therapeutic development and manufacturing increases
Solution Approach 1:
The patent develops antibody molecules with specifically optimized binding affinity parameters to PD-1, creating variants with different affinity levels (e.g., EC50 values ranging from low nM to high nM range) to achieve effective immune activation while managing therapeutic complexity through parameter optimization rather than structural complexity
Solution Approach 2:
The anti-PD-1 antibody molecules are designed to perform multiple functions: blocking PD-1/PD-L1 interaction, enhancing T-cell activation, and potentially serving as a platform for various administration routes and combination therapies, thereby reducing overall therapeutic development complexity through a versatile molecular platform
2Object-affected harmful factors
If specific anti-PD-1 antibody molecules are designed to block PD-1 ligand binding, then tumor immunosuppression is reduced, but the precision required in antibody design and manufacturing increases
Solution Approach 1:
The patent introduces specific mutations in the complementarity-determining regions (CDRs) of the antibody molecules to achieve localized optimization of PD-1 binding specificity, allowing precise blocking of immunosuppressive interactions while maintaining manufacturability through targeted rather than genome-wide precision requirements
Solution Approach 2:
The patent creates multiple antibody variants based on a parent anti-PD-1 antibody sequence, using iterative copying and mutation approaches to generate affinity-matured variants that achieve high specificity while simplifying manufacturing through standardized production platforms for antibody variants
3Productivity
If anti-PD-1 antibody therapy is administered to enhance anti-tumor immunity, then cancer treatment outcomes may be improved, but the dosing regimen complexity and treatment monitoring requirements increase
Solution Approach 1:
The patent enables periodic administration of anti-PD-1 antibody therapy at optimized intervals (e.g., every 2-6 weeks) based on the pharmacokinetics and immunological memory effects, simplifying dosing regimens through established periodic schedules rather than continuous or highly frequent administration
Solution Approach 2:
The patent incorporates biomarker-based feedback mechanisms (e.g., PD-L1 expression levels, T-cell activation markers, tumor response assessment) to guide dosing decisions, thereby managing treatment complexity through objective monitoring rather than empirical or overly complex protocols
Data Source
AI summary
Antibody molecules that specifically bind to PD-1 are disclosed. The antibody molecules can be used to treat or prevent cancerous or infectious conditions and disorders.